RCKT Quote, Financials, Valuation and Earnings

Pfizer has a net margin of -- compared to Rocket Pharmaceuticals's net margin of 21.63%. Rocket Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.72%.

Rocket Pharmaceuticals has a consensus price target of $9.03, signalling upside risk potential of 263.74%. On the other hand Pfizer has an analysts' consensus of $29.14 which suggests that it could grow by 13.62%. Given that Rocket Pharmaceuticals has higher upside potential than Pfizer, analysts believe Rocket Pharmaceuticals is more attractive than Pfizer.

Rocket Pharmaceuticals has a beta of 0.668, which suggesting that the stock is 33.232% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.63% to investors and pays a quarterly dividend of $0.43 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Rocket Pharmaceuticals's net income of -$61.3M is lower than Pfizer's net income of $3B. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 2.34x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -- compared to Rocket Pharmaceuticals's net margin of 6.83%. Rocket Pharmaceuticals's return on equity of -- beat Regenxbio's return on equity of -50.09%.

Rocket Pharmaceuticals has a consensus price target of $9.03, signalling upside risk potential of 263.74%. On the other hand Regenxbio has an analysts' consensus of $31.75 which suggests that it could grow by 265.78%. Given that Regenxbio has higher upside potential than Rocket Pharmaceuticals, analysts believe Regenxbio is more attractive than Rocket Pharmaceuticals.

Rocket Pharmaceuticals has a beta of 0.668, which suggesting that the stock is 33.232% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.051%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Regenxbio quarterly revenues of $89M. Rocket Pharmaceuticals's net income of -$61.3M is lower than Regenxbio's net income of $6.1M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 2.82x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -- compared to Rocket Pharmaceuticals's net margin of -271.3%. Rocket Pharmaceuticals's return on equity of -- beat Spero Therapeutics's return on equity of -108.26%.

Rocket Pharmaceuticals has a consensus price target of $9.03, signalling upside risk potential of 263.74%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 77.94%. Given that Rocket Pharmaceuticals has higher upside potential than Spero Therapeutics, analysts believe Rocket Pharmaceuticals is more attractive than Spero Therapeutics.

Rocket Pharmaceuticals has a beta of 0.668, which suggesting that the stock is 33.232% less volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.062%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Spero Therapeutics quarterly revenues of $5.1M. Rocket Pharmaceuticals's net income of -$61.3M is lower than Spero Therapeutics's net income of -$13.9M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 5.41x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Rocket Pharmaceuticals's net margin of -60.08%. Rocket Pharmaceuticals's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

Rocket Pharmaceuticals has a consensus price target of $9.03, signalling upside risk potential of 263.74%. On the other hand Sarepta Therapeutics has an analysts' consensus of $47.96 which suggests that it could grow by 163.95%. Given that Rocket Pharmaceuticals has higher upside potential than Sarepta Therapeutics, analysts believe Rocket Pharmaceuticals is more attractive than Sarepta Therapeutics.

Rocket Pharmaceuticals has a beta of 0.668, which suggesting that the stock is 33.232% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Rocket Pharmaceuticals's net income of -$61.3M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 0.90x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.